Analysts See $-1.19 EPS for Theravance Biopharma, Inc. (TBPH) as of May, 8

April 17, 2018 - By Michael Garrison

Theravance Biopharma, Inc. (NASDAQ:TBPH) Corporate Logo
During Q4 2017 the big money sentiment decreased to 1.31. That’s change of 0.01, from 2017Q3’s 1.32. 7 investors sold all, 22 reduced holdings as Theravance Biopharma, Inc. ratio is negative. 26 increased stakes while 12 funds bought stakes. Funds hold 35.06 million shares thus 1.11% less from 2017Q3’s 35.46 million shares.
Proshare Advsrs Ltd reported 0.01% in Theravance Biopharma, Inc. (NASDAQ:TBPH). Rock Springs Capital Management Lp accumulated 652,600 shs. Citigroup Inc accumulated 358 shs. Bancorporation Of Montreal Can holds 693 shs. Royal Bank Of Canada owns 13,622 shs. Massachusetts-based Baupost Gru Lc Ma has invested 2.57% in Theravance Biopharma, Inc. (NASDAQ:TBPH). Voya Lc holds 0% or 18,950 shs. Balyasny Asset Mgmt Limited Liability Company reported 88,692 shs. Alliancebernstein L P holds 0% or 61,235 shs in its capital. D E Shaw And Inc stated it has 87,584 shs. Foundation Asset L P invested in 3.63% or 432,532 shs. Barclays Public Limited Co has invested 0% in Theravance Biopharma, Inc. (NASDAQ:TBPH). Tiaa Cref Mngmt Limited Liability Corporation stated it has 0% in Theravance Biopharma, Inc. (NASDAQ:TBPH). Dekabank Deutsche Girozentrale has invested 0.01% in Theravance Biopharma, Inc. (NASDAQ:TBPH). New York-based Blackrock Incorporated has invested 0% in Theravance Biopharma, Inc. (NASDAQ:TBPH).

Theravance Biopharma, Inc. (NASDAQ:TBPH)’s earnings release is expected by WallStreet on May, 8, according to Zacks. Analysts predict $-1.19 EPS. That’s $0.08 up or 6.30 % from 2017’s earnings of $-1.27. After $-1.64 EPS report last quarter, Wall Street now sees -27.44 % EPS growth of Theravance Biopharma, Inc.. TBPH reached $22.78 on during the last trading session after $0.22 change.Theravance Biopharma, Inc. has volume of 65,354 shares. Since April 17, 2017 TBPH has declined 26.76% and is downtrending. The stock underperformed the S&P500 by 38.31%.

Theravance Biopharma, Inc. (NASDAQ:TBPH) Ratings Coverage

Total analysts of 5 have positions in Theravance Biopharma (NASDAQ:TBPH) as follows: 4 rated it a “Buy”, 1 with “Sell” and 0 with “Hold”. The positive are 80%. Since October 30, 2017 according to StockzIntelligence Inc Theravance Biopharma has 6 analyst reports. On Thursday, February 8 Leerink Swann maintained Theravance Biopharma, Inc. (NASDAQ:TBPH) with “Outperform” rating. On Monday, October 30 Robert W. Baird maintained Theravance Biopharma, Inc. (NASDAQ:TBPH) rating. Robert W. Baird has “Sell” rating and $22.0 target. On Thursday, March 29 Piper Jaffray initiated Theravance Biopharma, Inc. (NASDAQ:TBPH) rating. Piper Jaffray has “Buy” rating and $4500 target. In Wednesday, November 8 report Needham maintained the stock with “Buy” rating. On Tuesday, February 27 Cantor Fitzgerald maintained the shares of TBPH in report with “Buy” rating. On Tuesday, November 7 the stock of Theravance Biopharma, Inc. (NASDAQ:TBPH) earned “Buy” rating by Cantor Fitzgerald.

Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics.The company has $1.25 billion market cap. The firm offers VIBATIV , a bactericidal, once-daily injectable antibiotic to treat patients with infections due to Staphylococcus aureus and other Gram-positive bacteria.Last it reported negative earnings. The Company’s product candidates include TD-1792 that is in phase III clinical trials for the treatment of skin and soft tissues infections; TD-6450, a multivalent NS5A inhibitor, which is in Phase II study for Hepatitis C Virus; and Revefenacin (TD-4208), a long acting muscarinic antagonist that is in Phase III clinical studies for chronic obstructive pulmonary diseases.

Theravance Biopharma, Inc. (NASDAQ:TBPH) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.